Compare MFIC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | TBPH |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 993.7M |
| IPO Year | 2004 | N/A |
| Metric | MFIC | TBPH |
|---|---|---|
| Price | $11.38 | $19.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $12.63 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 833.1K | 505.0K |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | 0.58 |
| Revenue | ★ $324,678,000.00 | $80,327,000.00 |
| Revenue This Year | $9.15 | $70.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $10.73 | $32.83 |
| Revenue Growth | 11.35 | ★ 27.12 |
| 52 Week Low | $10.18 | $7.90 |
| 52 Week High | $14.74 | $20.33 |
| Indicator | MFIC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 64.36 |
| Support Level | $11.04 | $17.59 |
| Resistance Level | $11.65 | $19.25 |
| Average True Range (ATR) | 0.22 | 0.59 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 44.44 | 95.00 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).